What's Going On With Greenwich LifeSciences Friday?

Benzinga_recent_news

2025/12/27

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock rose Friday, even as the company disclosed no new announcements to explain the move. The stock action follows a corporate update earlier this week ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2594297724"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594297724\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594297724?lang=zh_TW&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/26/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-27 01:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594297724","market":"sh","top_or_hot":-1,"title":"What's Going On With Greenwich LifeSciences Friday?","media":"Benzinga_recent_news","content":"<div>\n<p>Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock rose Friday, even as the company disclosed no new announcements to explain the move.\nThe stock action follows a corporate update earlier this week ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49596114/whats-going-on-with-greenwich-lifesciences-friday\">网页链接</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Greenwich LifeSciences Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Greenwich LifeSciences Friday?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga_recent_news</strong><span class=\"h-time small\">2025-12-27 01:03</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock rose Friday, even as the company disclosed no new announcements to explain the move.\nThe stock action follows a corporate update earlier this week ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49596114/whats-going-on-with-greenwich-lifesciences-friday\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.benzinga.com/news/health-care/25/12/49596114/whats-going-on-with-greenwich-lifesciences-friday\">Benzinga_recent_news</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLSI","symbol_name":"Greenwich Lifesciences Inc","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/12/49596114/whats-going-on-with-greenwich-lifesciences-friday","article_id":"2594297724","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/26/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49596114/whats-going-on-with-greenwich-lifesciences-friday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594297724","pubTimestamp":1766768580,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Greenwich LifeSciences stock hits a new 52-week high! Discover how Greenwich LifeSciences is streamlining its Phase 3 FLAMINGO-01 trial.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLSI":"Greenwich Lifesciences Inc","BK4139":"生物科技"},"translate_title":"格林威治生命科学周五发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLSI":1},"content_text":"Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock rose Friday, even as the company disclosed no new announcements to explain the move.\nThe stock action follows a corporate update earlier this week outlining progress in the company’s Phase 3 FLAMINGO-01 clinical trial and broader efforts to reduce risk, manage costs, and position the business for potential partnerships as enrollment momentum builds.\nThe update highlighted growing patient interest in GLSI-100, an immunotherapy being evaluated to prevent breast cancer recurrence.\nAlso Read: Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine?\nFLAMINGO-01 currently has about 140 active sites enrolling patients, with plans to activate 10 additional approved sites in 2026 and expand into more European Union countries.\nThe company said investigator interest has increasingly shifted to patient-driven demand, with some sites reporting waitlists.\nGreenwich LifeSciences is also evaluating operational changes aimed at improving trial quality and lowering expenses.\nThese include bringing more clinical trial operations in-house and discontinuing the use of a contract research organization for U.S. and global trial management.\nThe management said its at-the-market facility is being used conservatively to align with the company’s cash burn, which has averaged about $7 million annually in recent years.\nWhile reported net losses were higher due to non-cash stock-based compensation, operational cash usage remained comparatively low. For the first three quarters of 2025, the burn rate remained near $7 million, supported by a lean structure and cost-saving measures.\nThe FLAMINGO-01 Data Safety Monitoring Board met twice in 2025, most recently in December, and recommended continuing the study without changes.\nThe Steering Committee, which met during SABCS 2025, endorsed planned protocol modifications pending regulatory approval, including expanding study size, increasing enrollment rates, and using interim analyses to potentially adjust study parameters.\nGLSI Price Action: Greenwich LifeSciences shares were up 16.21% at $19.99 at the time of publication on Friday. The stock is trading at a new 52-week high, according to Benzinga Pro data.\nRead Next:\nImage via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}